Healthequity (NASDAQ:HQY) Price Target Raised to $90.00 at Raymond James

Healthequity (NASDAQ:HQY) had its target price increased by Raymond James from $85.00 to $90.00 in a research report released on Friday morning, The Fly reports. The firm currently has an outperform rating on the stock.

Several other research analysts also recently weighed in on HQY. Zacks Investment Research downgraded HENGAN INTL GRP/ADR from a strong-buy rating to a hold rating in a research note on Tuesday, May 21st. JPMorgan Chase & Co. set a $69.00 price target on Helmerich & Payne and gave the stock a buy rating in a research note on Wednesday, June 5th. Citigroup reiterated a buy rating on shares of Healthequity in a research note on Friday, June 28th. BidaskClub downgraded Vertex Pharmaceuticals from a buy rating to a hold rating in a research note on Tuesday, July 9th. Finally, Bank of America downgraded Public Service Enterprise Group from a buy rating to a neutral rating and set a $65.00 price target for the company. in a research note on Friday. One research analyst has rated the stock with a hold rating and thirteen have issued a buy rating to the stock. The stock presently has a consensus rating of Buy and a consensus price target of $87.92.

Shares of NASDAQ:HQY opened at $79.97 on Friday. The company has a market cap of $4.97 billion, a P/E ratio of 84.18, a PEG ratio of 3.93 and a beta of 1.46. The company has a debt-to-equity ratio of 0.07, a current ratio of 15.60 and a quick ratio of 15.59. The company has a fifty day simple moving average of $68.37. Healthequity has a 1 year low of $50.29 and a 1 year high of $101.58.

Healthequity (NASDAQ:HQY) last announced its quarterly earnings data on Tuesday, June 4th. The company reported $0.36 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.25 by $0.11. The firm had revenue of $87.05 million during the quarter, compared to the consensus estimate of $83.98 million. Healthequity had a return on equity of 14.17% and a net margin of 30.60%. On average, sell-side analysts forecast that Healthequity will post 1.01 EPS for the current year.

In related news, CEO Jon Kessler bought 10,000 shares of the business’s stock in a transaction on Friday, July 12th. The stock was acquired at an average price of $61.00 per share, for a total transaction of $610,000.00. Following the purchase, the chief executive officer now directly owns 442,410 shares in the company, valued at $26,987,010. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Darcy G. Mott sold 4,000 shares of the firm’s stock in a transaction dated Thursday, June 20th. The stock was sold at an average price of $71.69, for a total value of $286,760.00. Following the completion of the transaction, the chief financial officer now owns 58,000 shares of the company’s stock, valued at approximately $4,158,020. The disclosure for this sale can be found here. Insiders have sold a total of 27,024 shares of company stock valued at $1,912,611 in the last quarter. 3.70% of the stock is owned by corporate insiders.

Hedge funds and other institutional investors have recently modified their holdings of the business. Manchester Capital Management LLC bought a new position in Healthequity in the 1st quarter worth about $36,000. Global Retirement Partners LLC boosted its stake in Healthequity by 72.7% in the 1st quarter. Global Retirement Partners LLC now owns 556 shares of the company’s stock worth $41,000 after purchasing an additional 234 shares during the period. Financial Gravity Wealth Inc. bought a new position in Healthequity in the 1st quarter worth about $45,000. Quantamental Technologies LLC raised its holdings in shares of Healthequity by 5,683.3% in the 1st quarter. Quantamental Technologies LLC now owns 694 shares of the company’s stock valued at $51,000 after acquiring an additional 682 shares in the last quarter. Finally, Signaturefd LLC raised its holdings in shares of Healthequity by 24.3% in the 1st quarter. Signaturefd LLC now owns 803 shares of the company’s stock valued at $59,000 after acquiring an additional 157 shares in the last quarter. Institutional investors and hedge funds own 95.98% of the company’s stock.

Healthequity Company Profile

HealthEquity, Inc provides various solutions for managing health care accounts, health reimbursement arrangements, and flexible spending accounts for health plans, insurance companies, and third-party administrators in the United States. The company offers healthcare saving and spending platform, a cloud-based platform for individuals to make health saving and spending decisions, pay healthcare bills, compare treatment options and prices, receive personalized benefit and clinical information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.

Featured Story: How do taxes affect a CDs total return?

The Fly

Analyst Recommendations for Healthequity (NASDAQ:HQY)

Receive News & Ratings for Healthequity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Healthequity and related companies with's FREE daily email newsletter.